EZR-104 FDA Approval Status
EZR-104 (valsartan) is a novel formulation of the angiotensin receptor blocker valsartan, with patented RubiretenTM delivery technology, in development for the treatment of hypertension and heart failure.
Development Timeline for EZR-104
|Jan 18, 2017||Ezra Announces FDA Acceptance of Filing of New Drug Application For EZR-104 for the Treatment of Hypertension and Heart Failure|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.